The serum samples corresponding to the DBSs from the main study were thawed and analyzed on the AutoDELFIA for PAPP-A
(kit reference B098-201) and free hCG[beta] (kit reference B097-101), as well as for intact hCG (kit reference B082-101), which was measured as a potential explanatory variable for predicting DBS free-hCG[beta] concentrations.
Interpretive Question: Maternal Weight Adjustment for PAPP-A
There was no significant difference in PAPP-A
concentrations in deceased patients and survivors [4.
(MoM) decreased, the LR increased for all 3 trisomies (see online Supplemental Fig.
To document the relationship between sustained subcutaneous LMWH administration and serum PAPP-A
concentration more clearly, we also measured the serum LMWH concentration by high-performance Capillary electrophoresis.
Serum samples for PAPP-A
were collected at the time of hospital admission.
We prepared and quantified recombinant human PAPP-A
as described (15).
calibrators were prepared from a filtered (0.
Paradoxically, there is substantial evidence from the clinical perspective, rather than from the theoretical laboratory approach, that PAPP-A
is a useful prognostic marker in ACS.
The proteolytic activity of PAPP-A
is directed specifically toward insulin-like growth factor (IGF)-binding proteins, and thus it allows the release of active IGF-1 and promotes the proatherogenic effects of IGF-1 (10).
is a zinc-binding metalloproteinase (8) that specifically degrades insulin-like growth factor (IGF)-binding proteins (9,10), thereby allowing unbound/active IGF to bind to cell-surface IGF receptors (11, 12).
has been shown to be present in unstable coronary atherosclerotic plaques (7), and increased circulating PAPP-A
concentrations are associated with acute coronary syndromes (ACS) (7,8).